openPR Logo
Press release

New Technologies for HPAPI Manufacturing and Containment

08-29-2019 10:30 AM CET | Media & Telecommunications

Press release from: SMi Group Ltd

New Technologies for HPAPI Manufacturing and Containment

SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production.

At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures.

Key highlights include:

Alternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing
- Alternative drug manufacture through nanocrystal formulations, thin films and hot-melt extrusion/injection moulding that reduces HPAPI powder exposure and improve safety
- Detailing step-by-step process along with the equipment needed to achieve these alternative HPAPI manufacturing techniques
- The advantages of continuous manufacturing utilizing alternative manufacturing technologies

Respiratory HPAPIs: development, formulation and delivery
- Advantages and targets of a respiratory HPAPI
- Equipment and analytical instruments that are most suitable for respiratory containment and safe handling
- Strategies for the development and industrialization process to ensure respiratory HPAPI success
- The current trends in respiratory HPAPIs

Training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management
- Staff training - understanding the equipment they are using
- Due diligence for management to continually assess the HPAPI workspace and keeping operators up to date
- Understand the need to establish expectations surrounding the safe handling of HPAPI

Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA
Conference: October 21st – 22nd
Workshops: October 23rd
Venue: Sheraton Boston Hotel, USA

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168

1 Westminster Bridge Road

Event organisers

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Technologies for HPAPI Manufacturing and Containment here

News-ID: 1827795 • Views: 704

More Releases from SMi Group Ltd

Co-chairs invitation to attend the Pharmaceutical Cleanrooms Conference in Londo …
SAE Media Group reports: Conference co-chairs invite you to attend the 2nd Annual Next Generation Pharmaceutical Cleanrooms this October 2022. The conference will be co-chaired by Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda, in which they have released an invitation letter for all interested parties. Excerpt of the Co-Chair invitation letter: 'As joint chairs of the 2nd Annual Next Generation Pharmaceutical Cleanrooms Conference, it is our
Exclusive Speaker Interview with Karen Capper, AstraZeneca ahead of the Pharmace …
SMi Group reports: exclusive speaker interview with microbiology expert Karen Capper, AstraZeneca about the developments in the microbiology field. Now in its 10th Annual year, the Pharmaceutical Microbiology UK conference is one not to be missed. Taking place on 17th and 18th January 2022 as a virtual conference with online access only. The conference will bring together industry experts to discuss and analyse the latest advancements and challenges within pharmaceutical microbiology. Interested
SMi’s 3D Cell Culture conference 2022 – Speakers announced
SMi Reports: Agenda and speaker overview of the upcoming 5th Annual 3D Cell Culture Conference. SMi Group is delighted to announce the return of the successful 3D Cell Culture Conference for its 5th year, taking place on 9th and 10th February 2022 in London, UK. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in
Maritime Safety Briefings to Look Forward to at Defence Safety 2020
Defence Safety 2020 will provide a comprehensive overview of safety within the military, aiming to review the safe delivery of defence capabilities, and the parts that operational users, equipment, and service delivery organisations, as well as research and development play. Once again supported by the UK MoD Defence Safety Authority, the event will feature a diverse, international speaker line-up of military and industry experts, who will explore the latest updates on

All 5 Releases

More Releases for HPAPI

HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report
SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project S …
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety